BREAKING: Zydus Cadila Applies For Emergency Use Nod From DCGI For Launch of Its Covid Vaccine For 12+ Age
New Delhi: In a major development, pharmaceutical company Zydus Cadila has applied for the Emergency Use Authorisation (EUA) from the Drugs Controller General of India (DCGI) for the launch of its DNA Covid-19 vaccine that can be administered to children aged 12 years as well as adults. The vaccine has completed the third phase of clinical trials. The company plans to manufacture up to 120 million doses of the shot annually.
The development comes as a great relief for children who are waiting to be vaccinated amidst the possibility of the third wave of Covid-19, which experts have warned may affect the kids primarily.
The Centre had earlier informed the Supreme Court that Zydus Cadila had concluded the clinical trials of its vaccine for the 12+ age group, and the shots would be available soon.
“It is submitted that Zydus Cadila which is developing DNA vaccines has concluded its clinical trial for between the age group of 12 to 18 years of age and subject to the statutory permissions, the same may be available in near future for children in the age group of 12 to 18 years of age,” the Centre had told the top court in an affidavit filed on COVID management.
AIIMS Chief Dr. Randeep Guleria had earlier stated that making Covid-19 vaccine available for children will be a milestone achievement and pave the way for the reopening of schools and resumption of outdoor activities for them.
Meanwhile, the data of phase two and three trials of Bharat Biotech’s Covaxin on two to 18 years age group is expected by September. Foreign vaccine Pfizer, which can be administered to children, is also in talks with the government and may come to India soon.
source https://www.india.com/news/india/breaking-zydus-cadila-applies-for-emergency-use-nod-dcgi-dna-covid-vaccine-zycov-d-vaccine-for-children-in-india-4780360/
Comments
Post a Comment